Sanjay Chanda
Corporate Officer/Principal bei AN2 THERAPEUTICS, INC.
Vermögen: 56 188 $ am 31.05.2024
Aktive Positionen von Sanjay Chanda
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| AN2 THERAPEUTICS, INC. | Corporate Officer/Principal | 01.11.2019 | - |
Cortene, Inc.
 Cortene, Inc. BiotechnologyHealth Technology Cortene, Inc. develops interventional treatment for myalgic encephalomyelitis. The company is headquartered in Burlingame, CA. | Corporate Officer/Principal | 01.02.2017 | - |
Karriereverlauf von Sanjay Chanda
Ehemalige bekannte Positionen von Sanjay Chanda
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Arch Oncology, Inc.
 Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | Corporate Officer/Principal | 01.01.2008 | 01.08.2017 |
| ANACOR PHARMACEUTICALS INC | Corporate Officer/Principal | 01.01.2008 | 01.10.2016 |
Auration Biotech, Inc.
 Auration Biotech, Inc. Miscellaneous Commercial ServicesCommercial Services Auration Biotech, Inc. develops novel therapeutics for the treatment of diseases of the ear, nose, and throat. The private company is based in Dover, DE. The company was founded by Sanjay Chanda. Benjamin F. McGraw has been the CEO of the company since 2014. | Gründer | 01.01.2014 | - |
Ausbildung von Sanjay Chanda
| Birla Institute of Technology & Science | Graduate Degree |
| Northeast Louisiana University | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 7 |
| Indien | 2 |
Operativ
| Corporate Officer/Principal | 4 |
| Graduate Degree | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
| Commercial Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AN2 THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Anacor Pharmaceuticals LLC
 Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Anacor Pharmaceuticals, Inc. develops medical solutions. The firm operates as a biopharmaceutical company, which focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded by Lucy Shapiro, Stephen J. Benkovic, and David P. Perry in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | Commercial Services |
Auration Biotech, Inc.
Auration Biotech, Inc. Miscellaneous Commercial ServicesCommercial Services Auration Biotech, Inc. develops novel therapeutics for the treatment of diseases of the ear, nose, and throat. The private company is based in Dover, DE. The company was founded by Sanjay Chanda. Benjamin F. McGraw has been the CEO of the company since 2014. | Commercial Services |
Cortene, Inc.
Cortene, Inc. BiotechnologyHealth Technology Cortene, Inc. develops interventional treatment for myalgic encephalomyelitis. The company is headquartered in Burlingame, CA. | Health Technology |
- Börse
- Insiders
- Sanjay Chanda
- Erfahrung
